Heart and Blood Diseases

All Conditions

Diseases and Abnormalities at or Before Birth

Symptoms and General Pathology

Neoplasms

Aneurysm

Arteriovenous Malformations

Congenital Abnormalities

Constriction, Pathologic

Hemangioma

Vascular Diseases

Vascular Malformations

Cardiovascular Abnormalities

Neoplasms, Vascular Tissue

Neoplasms by Histologic Type

Low dose DSA (75% reduction compared to normal dose) with novel X-ray imaging technology

Normal dose DSA with conventional X-ray technology.

Digital substraction angiography (DSA) with reduced dose settings (75% reduction expected) in combination with conventional X-ray imaging technology.

Low dose DSA (75% reduction compared to normal dose) with novel X-ray imaging technology.

Digital substraction angiography (DSA) with normal dose settings in combination with conventional X-ray imaging technology.

Normal dose DSA with conventional X-ray technology

Michael Söderman, MD, PhD

Tommy Andersson, MD, PhD

Staffan Holmin, MD, PhD

ClarityIQ is a novel X-ray imaging technology, that combines advanced real-time image noise reduction algorithms, with state-of-the-art hardware to reduce patient entrance dose significantly. This is realized by anatomy-specific optimization of the full acquisition chain (grid switch, beam filtering, pulse width, spot size, detector and image processing engine) for every clinical task individually. Furthermore, smaller focal spot sizes and shorter pulses are used, which are known to positively influence image quality . The final effect on the clinical image quality is investigated in this study.

The advent of interventional neuroradiology (INR) has changed the treatment of neurovascular diseases by reducing the procedural invasiveness and the recovery time needed by patients, thus improving clinical outcome. However, INR procedures often require many high-quality digital substraction angiography (DSA) runs and long total fluoroscopy times, which can result in patients being exposed to considerable radiation doses levels.

In order to introduce a dose reduction technology the most important aspect is to validate the diagnostic image information. Philips has developed a real-time noise reduction algorithm for DSA in neuroradiology that is capable to reduce the patient entrance dose by 75% without loss of image quality.

Image Quality and Radiation Dose in Angiography

XRES4 Neuro Claim Study

Percentage of dose reduction of ClarityIQ vs. AlluraXper in Air Kerma (AK) calculated by AK/frame.

The images were evaluated in randomized, blinded, offline readings. The anonymized images were displayed in pairs, i.e. the reference image run on one monitor (randomly left or right side) with the corresponding quarter-dose image run on the adjacent monitor. Three neuroradiologists graded the arterial, capillary, and venous phases separately. For each characteristic the images quality (IQ) were rated on a scale of 1 to 5 as 1 (very poor), 2 (mediocre), 3 (average), 4 (good), 5 (very good/excellent). An overall IQ score (3-15) was calculated as the sum of the score for these characteristics.

A paired Student's t test is used to compare the overall IQ score between the 2 imaging techniques. If the upper limit of the 97.5% one-sided CI for the difference overall IQ between the two treatment groups does not exceed the pre-defined non-inferiority margin of 2.5 Clarity will be declared non-inferior to the current image acquisition settings for DSA.

Percentage of dose reduction of ClarityIQ vs. AlluraXper in Dose Area Product (DAP) calculated by DAP/frame.

Philips Medical Systems

Karolinska University Hospital

MD, PhD

Angiogram with AlluraXper subsequently followed by angiogram with ClarityIQ

AlluraXper - ClarityIQ

Angiogram with AlluraXper followed by angiogram with ClarityIQ

Age, Continuous

Sex: Female, Male

Sweden

Region of Enrollment

Dr. Söderman

Investigator 1

Investigator 2

Investigator 3

AlluraXper

Allura Clarity

Image Quality. For Each Included Participant 2 Images (1 AlluraXper; 1 AlluraClarity) Were Evaluated.

All patients with recorded dose information and images for both angiograms were included (n=20)

Spots Global Cancer Trial Database for dural arteriovenous malformations